Online inquiry

IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5074MR)

This product GTTS-WQ5074MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Hidradenitis suppurativa (HS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5074MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10382MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ5781MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ3627MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ11492MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ7079MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ8467MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ1919MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ13085MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-00547659
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW